LYCOS RETRIEVER 
Organon: Organon Biosciences
built 623 days ago
Organon BioSciences is a globally operating biopharmaceutical company and wholly owned subsidiary of Akzo Nobel that develops, manufactures and markets products targeting selected therapeutic areas in human pharmaceuticals and covering a wide range of species in animal health. The Company's products enjoy leading positions in gynecology, infertility, selected areas of anesthesia and animal health. Organon Biosciences consists of two operating units: Organon is the human pharmaceuticals business and Intervet, the animal health business, is the third largest animal health company. Organon BioSciences markets its products on a worldwide basis in over 130 countries.
Source:
A Organon BioSciences é formada basicamente pela Organon, empresa de produtos farmacêuticos para seres humanos, e a Intervet, empresa para saúde de animais. Também inclui a Nobilon, unidade de desenvolvimento de vacinas humanas, e a Diosynth, unidade de fabricação para terceiros da Organon.
Source:
Organon BioSciences is comprised primarily of Organon, a human health business, and Intervet, an animal health business. It ... includes Nobilon, a human vaccine development unit, and Diosynth, a third-party manufacturing unit of Organon. Schering-Plough acquired Organon BioSciences from Akzo Nobel N.V. for approximately euro 11 billion in cash.
Source:
Schering-Plough agreed today to purchase the Organon Biosciences unit of Dutch company Akzo Nobel for 11 billion euros ($14.4 billion) cash. Akzo shares reached a five-year high on the news. Organon is the third-largest manufacturer of birth-control pills in the world. In addition to the contraceptive pill Marvelon and birth-control implant Implanon, five experimental drugs in advanced clinical trials will be added to Schering-Plough's roster by the transaction as well as "a number of promising projects'' at earlier stages. Akzo elected to sell Organon after sales disappointed last year and its asenapine schizophrenia drug, considered by analysts to have blockbuster potential, was delayed -- a development that may have steered Akzo's management away from an IPO of Organon, which it had ... been considering. Schering-Plough forecasts the deal will raise EPS by $0.10 in the first year after one-time costs and adjustments.
Source:
Eden not only regenerated the visual identity of Organon but ... developed a completely new style for Organon BioSciences (OBS). The intention was to float the pharmaceutical division of Akzo Nobel on the stock exchange under this name at the end of March 2007. However, with the sale of Organon and Intervet to the American company Schering-Plough, Organon BioSciences will cease to exist once the sale is closed.
Source:
On March 12, 2007, Schering Plough announced its intention to acquire Organon BioSciences for € 11 billion. During the course of several months the necessary approvals have been granted by the EU (amongst others). Organon BioSciences is now a part of the Schering Plough corp.[1]
Source:
MORE ABOUT
Organon Biosciences